Vusolimogene oderparepvec

迪合沃索基

Report date: 2026/05/16 20:00:17

Base Information

Drug NameVusolimogene oderparepvec
Drug Alias NameRP-1
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsMacrophage colony stimulating factor 2 Gene transference
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsSkin MelanomaMicrosatellite instability-high cancerCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesReplimune Group Inc
China Registration ClassN/A

Develop Information

Active CompaniesReplimune Inc
Inactive CompaniesN/A
Active IndicationsSkin MelanomaMicrosatellite instability-high cancerCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A